- Home
- FLNG vs NVCR Comparison
FLNG vs NVCR Comparison
Compare FLNG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- NVCR
- Stock Information
- Founded
- FLNG 2006
- NVCR 2000
- Country
- FLNG Bermuda
- NVCR Switzerland
- Employees
- FLNG N/A
- NVCR N/A
- Industry
- FLNG Marine Transportation
- NVCR Medical/Dental Instruments
- Sector
- FLNG Consumer Discretionary
- NVCR Health Care
- Exchange
- FLNG Nasdaq
- NVCR Nasdaq
- Market Cap
- FLNG 1.3B
- NVCR 1.4B
- IPO Year
- FLNG N/A
- NVCR 2015
- Fundamental
- Price
- FLNG $25.26
- NVCR $12.15
- Analyst Decision
- FLNG Hold
- NVCR Buy
- Analyst Count
- FLNG 1
- NVCR 7
- Target Price
- FLNG $23.00
- NVCR $28.79
- AVG Volume (30 Days)
- FLNG 537.5K
- NVCR 1.3M
- Earning Date
- FLNG 11-11-2025
- NVCR 10-29-2025
- Dividend Yield
- FLNG 11.87%
- NVCR N/A
- EPS Growth
- FLNG N/A
- NVCR N/A
- EPS
- FLNG 1.83
- NVCR N/A
- Revenue
- FLNG $355,837,000.00
- NVCR $630,160,000.00
- Revenue This Year
- FLNG N/A
- NVCR $6.68
- Revenue Next Year
- FLNG $3.41
- NVCR $7.01
- P/E Ratio
- FLNG $13.92
- NVCR N/A
- Revenue Growth
- FLNG N/A
- NVCR 14.58
- 52 Week Low
- FLNG $19.46
- NVCR $10.87
- 52 Week High
- FLNG $27.67
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- FLNG 44.33
- NVCR 46.57
- Support Level
- FLNG $24.65
- NVCR $11.98
- Resistance Level
- FLNG $26.04
- NVCR $12.83
- Average True Range (ATR)
- FLNG 0.56
- NVCR 0.56
- MACD
- FLNG -0.27
- NVCR 0.15
- Stochastic Oscillator
- FLNG 20.20
- NVCR 25.49
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.